Funding agency DST

Start date Nov. 17, 2023

End Date None

Duration None

Disease category Spinal Muscular Atrophy

Type of study Invitro study

Type of data Quantitative data

Aims of objective • To Develop a non-fringing synthetic route of Risdiplamto meet the need of people suffering from SMA in India and across the globe. • To perform in vitro & preclinical evaluation of the drug formulation. • To develop the novel route of synthesis, and formulation would reduce the cost of drug substance and drug formulation respectively and enhance the efficacy. This will ultimately reduce the burden among Indian populations in particular infants and young children.

Keyword Risdiplam, Spinal Muscular Atrophy, Rare disorder

Description None

Total Sanctioned budget None